Holen Sie sich die Stockscreener-App
1.94
9.27%
0.16
Handel nachbörslich:
1.91
-0.03
-1.55%
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
CRDF Technical Analysis | Trend, Signals & Chart Patterns | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Is Cardiff Oncology (CRDF) 5.1% Undervalued After Q1 2026 Earnin - GuruFocus
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $6 to $10 - Moomoo
Cardiff Oncology (CRDF) Reports Positive Trial Data and Leadersh - GuruFocus
Cardiff Oncology (CRDF) Secures Funding Through 1Q27 - GuruFocus
Cardiff Oncology Q1 net loss narrows as operating expenses fall - TradingView
Cardiff Oncology earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology: Q1 Earnings Snapshot - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) details Q1 2026 loss and Phase 3 plans - Stock Titan
FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) posts Q1 loss, warns on cash and details onvansertib data - Stock Titan
Cardiff Oncology, Inc.Common Stock (NQ: CRDF - FinancialContent
CRDF Stock Price, Quote & Chart | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
Cardiff Oncology (CRDF) to Release Earnings on Thursday - MarketBeat
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - GlobeNewswire
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):